NEW ORLEANS -- An investigational antibody targeting interleukin (IL)-31 in prurigo nodularis significantly reduced itch, skin lesions, and sleep disturbance in a phase III trial. More than half of ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results